@article {Naseri2020.10.26.20220004, author = {Ardalan Naseri and Degui Zhi and Shaojie Zhang}, title = {Discovery of runs-of-homozygosity diplotype clusters and their associations with diseases in UK Biobank}, elocation-id = {2020.10.26.20220004}, year = {2020}, doi = {10.1101/2020.10.26.20220004}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Runs of homozygosity (ROH) segments, contiguous homozygous regions in a genome were traditionally linked to families and inbred populations. However, a growing literature suggests that ROHs are ubiquitous in outbred populations. Still, most existing genetic studies of ROH in populations are limited to aggregated ROH content across the genome, which does not offer the resolution for mapping causal loci. This limitation is mainly due to a lack of methods for efficient identification of shared ROH diplotypes. Here, we present a new method, ROH-DICE, to find large ROH diplotype clusters, sufficiently long ROHs shared by a sufficient number of individuals, in large cohorts. ROH-DICE identified over 1 million ROH diplotypes that span over 100 SNPs and shared by more than 100 UK Biobank participants. Moreover, we found significant associations of clustered ROH diplotypes across the genome with various self-reported diseases, with the strongest associations found between the extended HLA region and autoimmune disorders. We found an association between a diplotype covering the HFE gene and haemochromatosis, even though the well-known causal SNP was not directly genotyped nor imputed. Using genome-wide scan, we identified a putative association between carriers of an ROH diplotype in chromosome 4 and an increase of mortality among COVID-19 patients. In summary, our ROH-DICE method, by calling out large ROH diplotypes in a large outbred population, enables further population genetics into the demographic history of large populations. More importantly, our method enables a new genome-wide mapping approach for finding disease-causing loci with multi-marker recessive effects at population scale.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAN, SZ and DZ were supported by the National Institutes of Health grant R01 HG010086. AN and DZ were also supported by the National Institutes of Health grant OT2 OD002751.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been conducted using the UK Biobank Resource under Application Number 24247. All data collection was done by the UK Biobank prior to this research. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the UK Biobank Resource is available by application (https://www.ukbiobank.ac.uk).}, URL = {https://www.medrxiv.org/content/early/2020/10/27/2020.10.26.20220004}, eprint = {https://www.medrxiv.org/content/early/2020/10/27/2020.10.26.20220004.full.pdf}, journal = {medRxiv} }